Agilent Technologies, Inc. (A) | The Buildout — AI Infrastructure
The Verdict
Agilent Technologies provides laboratory instruments, consumables, services, and contract manufacturing (CDMO) that cover the full analytical workflow from sample preparation to data management. Its products are the picks-and-shovels layer for the life sciences industry, enabling the testing and quality control that drug development depends on. As AI accelerates drug discovery, the demand for analytical instruments and consumables stands to rise, positioning Agilent as an indirect but integral part of the AI-driven healthcare innovation pipeline.
| Market Cap | — |
| Revenue (TTM) | $7.2B |
| Revenue Growth | +9.1% |
| EBITDA Margin (TTM) | 25.3% |
| Net Debt | $1.5B |
| Earnings Beats | 5 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Nine straight quarters of instrument book-to-bill ≥1, driven by replacement cycle and share gains.
- Strategic pricing delivered 200 bps in Q2, double the full-year target, signaling structural pricing power.
- Ignite operating system structurally embedded, compounding cost savings and accelerating innovation; manufacturing overhead cut >50 bps YoY, product launch accelerated one quarter.
- Pharma reshoring represents a $1 billion addressable market through 2030, with zero revenue today and initial orders expected by end of FY2026.
- CDMO (Advanced Therapeutics) mid-teens growth; Train C mechanically complete with revenue starting spring 2027 and demand booked into FY2027.
What We’re Watching
- China revenue declined 9% in Q2; full-year flattish outlook maintained, but risk remains if stimulus is delayed.
- Small/mid biotech spending still lagging despite improved funding environment; the time lag between funding and instrument purchases could delay expected recovery.
- Middle East conflict injecting cost inflation (memory chips, logistics); while currently absorbed, escalation could pressure margins.
- The instrument replacement cycle may peak once the aged-fleet backlog is worked through; future growth then depends on innovation and new catalyst conversion.
The thesis is strengthening. Agilent is delivering broad-based organic growth with expanding margins, driven by a durable instrument replacement cycle, structural pricing power, and the compounding Ignite operating system. A rich pipeline of catalysts — pharma reshoring, CDMO capacity, AI adoption in drug discovery, and diagnostics expansion — remain unrealized, creating potential upside. The key open question is whether the current momentum is cyclical or truly structural, and whether China softness and macro risks can be absorbed without derailing growth.
Earnings Beat
Revenue reached $1.83 billion, up 6.3% on a core organic constant-currency basis, driven by low-double-digit instrument growth. Gross margin expanded 90 bps to 55.0%, and operating margin rose 130 bps to 26.4%, well above guidance. EPS of $1.49 grew 14% year-over-year.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $1.8B | $1.8B | $1.7B | +10.0% |
| Gross margin | 55.0% | 52.6% | 51.9% | +310bps |
| EBITDA | $466M | $420M | $373M | +24.9% |
| EPS | $1.19 | $1.07 | $0.75 | +58.2% |
Our strategic pricing capability delivered approximately 200 basis points of pricing in Q2, putting us on a path to exceed our initial full year goal of 100 basis points.— Padraig McDonnell, CEO, June 28, 2026
Management tone: Management's tone was confident and increasingly assertive, framing Ignite as structurally embedded and compounding. They were candid about China softness and food declines, while emphasizing the strength of order momentum and pricing.
Management Guidance
Full-year FY2026 guidance was raised: core organic revenue growth of 4.5%–6.0% (midpoint +30 bps), EPS $6.00–$6.10 (midpoint +$0.08), and operating margin expansion of ~85 bps (up from ~75 bps). The outlook assumes instruments continuing low-double-digit growth, consumables and services growth ex-China, and CDMO mid-teens growth, while absorbing Middle East cost inflation and China flattish performance. Biocare acquisition and potential tariff refunds are excluded.
Trajectory
Revenue has climbed from $1.58B in Q3 FY2024 to $1.83B in Q2 FY2026, with core growth of 6.3% in the latest quarter. Gross margin expanded to 55.0% from 51.9% a year ago, driven by pricing, volume leverage, and Ignite efficiencies. EBITDA margin rebounded to 25.4% from 22.4% in Q2 FY2025, reflecting operating leverage. The trajectory is supported by a strong instrument replacement cycle, broad-based end-market demand, and structural cost improvements.
The Model
The model projects FY+1 revenue of $7,560 million and EBITDA of $2,200 million (29.1% margin), reflecting continued organic growth and margin expansion. For FY+2, revenue reaches $8,200 million with EBITDA of $2,419 million (29.5%), driven by the expected contribution from pharma reshoring, CDMO capacity adds, and AI-accelerated drug-development testing demand.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $6.9B | $7.6B | $8.2B |
| YoY Growth | — | +8.8% | +8.5% |
| EBITDA | $1.8B | $2.2B | $2.4B |
| EBITDA Margin | 25.4% | 29.1% | 29.5% |
Projections are the median of 5 independent model runs. The model’s revenue sits 3.9% above analyst consensus.
Full-year FY2026 guidance was raised: core organic revenue growth of 4.5%–6.0% (midpoint +30 bps), EPS $6.00–$6.10 (midpoint +$0.08), and operating margin expansion of ~85 bps (up from ~75 bps). The outlook assumes instruments continuing low-double-digit growth, consumables and services growth ex-China, and CDMO mid-teens growth, while absorbing Middle East cost inflation and China flattish performance. Biocare acquisition and potential tariff refunds are excluded.
What Could Go Right — and Wrong
- Instrument replacement cycle sustains low-double-digit growth for 2-3 more years, with book-to-bill remaining ≥1 and new launches gaining traction.
- Pharma reshoring orders materialize on time and scale toward the $1 billion TAM, becoming a material revenue driver from FY2027.
- AI adoption in pharma accelerates drug approvals, boosting QA/QC testing and consumable pull-through across Agilent’s installed base.
- China stimulus and funding recovery drive a return to mid-single-digit growth, turning the current drag into a tailwind.
- Ignite continues to deliver compounding margin expansion, with pricing power sustained above 100 bps and overhead reductions extending.
- Instrument replacement cycle peaks and fades as the aged-fleet backlog is exhausted, leading to growth deceleration toward low single digits or decline.
- Pricing power proves transient, with competition or customer pushback causing pricing to revert toward historical levels, compressing margins.
- China structural decline persists beyond the flattish outlook, as government funding delays or local competition eat into Agilent's share.
- Reshoring orders and AI tailwinds fail to convert into revenue within the expected timeframe, leaving growth reliant solely on the replacement cycle.
- A severe geopolitical or macro shock (Middle East escalation, trade war) disrupts supply chains and freezes pharma CapEx, overwhelming mitigation.
Looking Ahead
The next twelve months will test whether Agilent's momentum can be sustained. Near term, the ASMS product launches will show if innovation extends the replacement cycle, while Q3 and Q4 earnings will confirm order and pricing durability. By fiscal year-end, the anticipated pharma reshoring orders would validate a new $1 billion addressable market. In the first half of 2027, CDMO Train C revenue and potential China stimulus should begin contributing, marking the next growth leg.
- July 2026ASMS product launches — Orders for new ICP-MS, GCs and columns test innovation-led replacement cycle
- Q3 FY2026Q3 FY2026 earnings — Tests tenth straight quarter of book-to-bill ≥1 and pricing durability
- Late FY2026Pharma reshoring orders — Initial orders expected; validates $1B addressable market opportunity
- Late FY2026China stimulus orders — Government lab funding orders could shift China from flat to growth
- Spring 2027CDMO Train C revenue begins — New capacity starts generating revenue; demand line-of-sight into FY2027
Financials
Annual Summary
| Metric | FY2025 | TTM |
|---|---|---|
| Revenue | $6.9B | $7.2B |
| Gross Margin | 52.5% | 53.0% |
| EBITDA | $1.8B | $3.5B |
| EBITDA Margin | 25.4% | 25.3% |
| Net Income | $1.3B | $1.4B |
| Free Cash Flow | $1.2B | $2.4B |
| Net Cash | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)53.0%
- EBITDA Margin (TTM)25.3%
- Net Margin (TTM)19.6%
- ROIC14.2%
- FCF Conversion68.6%
- SBC / Revenue1.8%
The Company
Agilent Technologies provides a comprehensive suite of laboratory instruments, consumables, services, and informatics software that cover the entire analytical workflow, from sample preparation to data management. It also operates a contract development and manufacturing organization (CDMO) for oligonucleotide-based therapeutics. Its products are used across pharmaceutical R&D and manufacturing, clinical diagnostics, chemical analysis, environmental testing, and forensics.
The company operates three segments: Life Sciences and Diagnostics Markets (LDG), which includes liquid chromatography, mass spectrometry, pathology, and the CDMO; Agilent CrossLab (ACG), encompassing consumables, services, and lab informatics; and Applied Markets (AMG), covering gas chromatography, spectroscopy, and vacuum technology. Agilent maintains a global manufacturing footprint with facilities in the U.S., Europe, and Asia, and distributes through direct sales, distributors, and e-commerce. It is increasingly embedding its Ignite operating system to drive pricing, cost efficiency, and innovation speed across the enterprise.
Business Segments
Competitive Landscape
Agilent competes across all segments with large, diversified players like Thermo Fisher Scientific, Danaher, and Waters. In its core liquid and gas chromatography markets, management claims to be gaining share, citing its strongest market-share data in years and nine consecutive quarters of book-to-bill above one. In CDMO, it competes with specialty firms like Avecia and Twist Bioscience. Barriers to switching are high owing to validated workflows and proprietary consumables.
- Thermo Fisher ScientificCompetes in LDG, ACG, AMG; a broad-based competitor.
- Danaher CorporationCompetes in LDG, ACG, AMG; strong in mass spectrometry and pathology.
- Waters CorporationCompetes in LDG, ACG, AMG; a direct rival in liquid chromatography.
- Shimadzu CorporationCompetes in LDG, ACG, AMG; also strong in GC and spectroscopy.
- Competes in LDG; noted for security detection and mass spectrometry; recent margin weakness highlighted.
Supply Chain
Agilent sits at the center of the lab-analytics ecosystem, sourcing custom components and electronics from specialty suppliers and distributing instruments and consumables to a diverse base of pharma, chemical, and diagnostics customers.